Clotting is initiated in the blood sample by an activator of the intrinsic pathways (such as celite, kaolin, and glass).ACT is a whole blood- clotting time test that initiates clotting and measures the time until clot formation.Overview of the Anticoagulation Monitoring Tests
Monitoring and Reversal of Anticoagulation and Antiplatelets. Inactivates thrombin (less affinity) and factor Xa (higher affinity)ĪCT = activated clotting time aPTT = activated partial thromboplastin time IV = intravenous LMWH = low molecular weight heparin POC = point of care subQ = subcutaneous UFH = unfractionated heparin.Īdapted from: Yost GW, Steinhubl SR. Inactivates factors IIa (thrombin) IXa, Xa, XIa, and XIIa Table 1: Anticoagulants for Cardiac Procedures The anticoagulant agents listed (Table 1) have been studied and/or are commonly used peri-procedurally for cardiac cases and meet several of the criteria listed above. 1,2 A point-of-care (POC) test for monitoring, such as during a case, has obvious advantages over a test that requires traditional venipuncture and laboratory measurement. The ideal anticoagulant should have an effect that is of short duration, be easy to monitor, and potentially reversible. The following summary is not an exhaustive review and will not discuss the specifics of anticoagulation therapy in depth. In this Tip of the Month, we focus on highlights related to anticoagulation monitoring in the cath lab. In order to optimize the safety of anticoagulation use, operators and cath lab staff need to be aware of the nuances of various tests, testing devices, and therapeutic goals. A key principle when using anticoagulation is to prevent the unintended consequences of bleeding and thrombosis. Beavers, PharmD, BCCP, BCPS-AQ Cardiology, CACP, and Jayant Bagai, MD, FSCAI IntroductionĬath lab procedures, such as percutaneous coronary interventions (PCIs), percutaneous mechanical circulatory support, transcatheter therapies, and ablation, are dependent on the use of anticoagulation therapy to reduce the associated thrombogenic potential. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.Ībbott - A Leader in Rapid Point-of-Care Diagnostics.Craig J. Check with your local representative for availability in specific markets. Not all products are available in all regions. GDPR Statement | Declaration for California Compliance Law. Any person depicted in such photographs is a model. Photos displayed are for illustrative purposes only. Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy.
WAIVED ACT ISTAT REGISTRATION
The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage. This website is governed by applicable U.S. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. Analytical performance of the i-STAT cardiac troponin I assay. Apple FS, Murakami MM, Christenson RH, et al. Impact of point-of-care testing in the emergency department evaluation and treatment of patients with suspected acute coronary syndromes. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction). 2009 53:321- 328.ģ. Third Universal Definition of Myocardial Infarction (MI), Kristian Thygesen, Joseph S.
WAIVED ACT ISTAT SERIAL
A multicenter randomized controlled trial comparing central laboratory and point-of-care marker testing strategies: The disposition impacted by serial point of care markers in acute coronary syndromes (DISPO-ACS) trial.
Irving, Tex: American College of Emergency Physicians April 2008.Ģ. Emergency Department Crowding: High-Impact Solutions. This page is only accessible to registered i-STAT customers.ġ. Reference ranges (sometimes referred to as normal ranges) in the default Customization profile can be found behind login on the i-STAT Cartridge and Test Information (CTI) Sheets/Instructions for Use (IFU) page.
0 kommentar(er)
